South America Dipeptide Peptidase 4 (DDP-4) Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The South America dipeptide peptidase 4 (DDP-4) inhibitors market is expected to increase from USD 582.42 million in 2025 to USD 605.68 million in 2026 to reach USD 766.83 million by 2031, at a CAGR of 4.83% during the forecast period (2026-2031). The market is supported by a growing number of adults living with diabetes, particularly in Brazil and Argentina. This report is segmented by Drug Type (Saxagliptin, Linagliptin, Alogliptin, Vildagliptin, Other Drug Types), Medication Type (Branded Medication, Generic Medication), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Country (Brazil, Argentina, Colombia, Chile, Peru, Rest of South America). Market Forecasts in Terms of Value (USD).

South America Dipeptide Peptidase 4 (DDP-4) Inhibitors Market Trends and Insights

Rising Type 2 Diabetes Prevalence

The International Diabetes Federation estimated that 35 million adults lived with diabetes across South and Central America in 2024, and 30.4%, or 10.7 million people, remained undiagnosed. Brazil recorded a clear increase in adult diabetes prevalence, from 5.5% in 2006 to 12.9% in 2024. The same national evidence linked the disease burden with excess weight affecting 60% of Brazilian adults. The South American DPP-4 inhibitors market, therefore, has a larger pool of patients who may need continuing glucose-lowering treatment after diagnosis. Primary-care screening in lower-income urban areas can bring people with episodic healthcare contact into treatment pathways. Affordable oral therapies can be important when those patients begin treatment outside specialist settings.

Growing Need for Weight-Neutral Oral Therapies

DPP-4 inhibitors provide a weight-neutral oral option, unlike sulfonylureas and insulin regimens that may create a risk of weight gain. This characteristic is important where obesity and type 2 diabetes commonly occur together and where treatment adherence can be affected by the burden of injectable care. Brazil’s 2025 clinical guidance retained DPP-4 inhibitors as treatment options for suitable patients with HbA1c below 7.5% who cannot access or tolerate GLP-1 receptor agonists or SGLT2 inhibitors. This guidance preserves a defined role for oral treatment within the South American DPP-4 inhibitors market, rather than treating the class as interchangeable with injectable therapies. Higher prices for injectable medicines can lead physicians and patients to consider weight-neutral oral alternatives. Generic availability can make that choice more accessible in price-sensitive settings and can preserve DPP-4 use while branded products face erosion.

Competition from GLP-1 Receptor Agonists and SGLT2 Inhibitors

The South American DPP-4 inhibitors market faces increased competition from GLP-1 receptor agonists and SGLT2 inhibitors. Lower-cost GLP-1 products can draw patients with obesity, high HbA1c levels, or cardiovascular risk toward injectable care. Brazil approved domestic production for liraglutide-based products in December 2024. Injectable therapies still require cold-chain handling and patient training. These requirements limit access beyond larger urban areas and specialist services. Oral DPP-4 therapies retain an operational advantage for primary care and rural use.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Combination Therapy Regimens
• Renal-Disease-Linked Preference for Linagliptin
• Reimbursement and Out-of-Pocket Affordability Constraints

Segment Analysis

Saxagliptin held 45.32% of value in 2025, making it the largest molecule in the South American DPP-4 inhibitors market. Its position was built through more than a decade of physician familiarity, earlier category-leading clinical trial data, and formulary placement in Brazil and Argentina. Branded Onglyza and a growing generic supply base support continuing use across hospital and private care settings. Generic supply helps sustain patient volumes even when branded unit prices decline. Linagliptin is forecasted to expand at a 5.22% CAGR through 2031 because it offers a distinct option for patients who also have chronic kidney disease.

The South American DPP-4 inhibitors market for linagliptin is supported by its biliary elimination, which removes the need for renal dose adjustments across chronic kidney disease stages. Clinical evidence associates linagliptin with a lower risk of hypoglycemia than sulfonylureas in patients with diabetes and chronic kidney disease. Vildagliptin retains a credible Brazilian private-care position through branded products and generic combinations with metformin, while alogliptin remains in selected institutional contracts.

Complete Report Scope:

• By Drug Type
  • Saxagliptin
  • Linagliptin
  • Alogliptin
  • Vildagliptin
  • Other Drug Types
• By Medication Type
  • Branded Medication
  • Generic Medication
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• By Country
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America

List of Companies Covered in this Report:

• AstraZeneca
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Eli Lilly and Company
• EMS S.A.
• Eurofarma Laboratorios S.A.
• Glenmark Pharmaceuticals
• GlaxoSmithKline
• Hypera S.A.
• Merck
• Novartis
• Pfizer
• Sandoz Group AG
• Sanofi
• Siegfried Holding AG
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
• Torrent Pharmaceuticals Limited
• Viatris
• Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support